Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neostigmine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05794503
View directory record Official record
Conditions
Urinary Retention Postoperative, Laparoscopic Cholecystectomy, Neuromuscular Blockade, Sugammadex, Neostigmine, Neuromuscular Blocking Agents, Physiological Effects of Drugs
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block

NCT05545280
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neostigmine with glycopyrrolate, Sugammadex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

NCT03579589
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex vs Neostigmine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jun 10, 2026, 2:32 PM EDT
Recruiting Phase 3 Interventional

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

NCT06136585
View directory record Official record
Conditions
Neuromuscular Blocks
Interventions
2 mg/kg sugammadex, 0.07 mg/kg neostigmine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 10, 2026, 2:32 PM EDT
Active, not recruiting Phase 3 Interventional

Neostigmine and Glycopyrrolate by Iontophoresis

NCT06351995
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

NCT03923556
View directory record Official record
Conditions
Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 10, 2026, 2:32 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Transdermal Administration by a Novel Wireless Iontophoresis Device

NCT06351852
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 10, 2026, 2:32 PM EDT
Terminated Phase 4 Interventional Results available

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

NCT05256901
View directory record Official record
Conditions
Appendicitis, Surgery
Interventions
Sugammadex, Neostigmine/Glycopyrrolate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

NCT03112993
View directory record Official record
Conditions
Spine Surgery
Interventions
sugammadex, Neostigmine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Jun 10, 2026, 2:32 PM EDT
Terminated Early Phase 1 Interventional

Neostigmine For Snoring During DISE

NCT03316963
View directory record Official record
Conditions
Snoring
Interventions
Neostigmine Methylsulfate
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

NCT03543826
View directory record Official record
Conditions
Muscle Weakness
Interventions
Protocol for rocuronium neuromuscular block
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

NCT02861131
View directory record Official record
Conditions
Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
70 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

NCT00001520
View directory record Official record
Conditions
Paralysis
Interventions
neostigmine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transdermal Iontophoresis of Vitamin B12 Under Three Different Skin Preparations

NCT04027959
View directory record Official record
Conditions
Macrocytic Anemia With Vitamin B12 Deficiency
Interventions
Vitamin B12
Dietary Supplement
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Jun 10, 2026, 2:32 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 10, 2026, 2:32 PM EDT
Completed No phase listed Observational

Reversal of Neuromuscular Blockade in Thoracic Surgical Patients

NCT01837498
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Jun 10, 2026, 2:32 PM EDT